131 related articles for article (PubMed ID: 34021511)
1. Initiation of four basal insulins and subsequent treatment modification in people treated for type 2 diabetes in the United Kingdom: Changes over the period 2003-2018.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabet Med; 2021 Aug; 38(8):e14603. PubMed ID: 34021511
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
[TBL] [Abstract][Full Text] [Related]
4. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
5. Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study.
Larose S; Filliter C; Platt RW; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Aug; 25(8):2279-2289. PubMed ID: 37165960
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
7. The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabetes Obes Metab; 2022 Nov; 24(11):2169-2181. PubMed ID: 35726454
[TBL] [Abstract][Full Text] [Related]
8. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
9. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
10. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Muthuri S; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
JAMA Intern Med; 2021 May; 181(5):598-607. PubMed ID: 33646277
[TBL] [Abstract][Full Text] [Related]
11. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
Lin JC; Shau WY; Lai MS
Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
13. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
14. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
15. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.
Dankers M; Hek K; Nelissen-Vrancken M; Houweling ST; Mantel-Teeuwisse A; van Dijk L
Br J Gen Pract; 2022 Jun; 72(719):e430-e436. PubMed ID: 35606162
[TBL] [Abstract][Full Text] [Related]
16. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
18. Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.
Kostev K; Dippel FW; Rockel T; Siegmund T
J Wound Care; 2012 Oct; 21(10):483-4, 486-9. PubMed ID: 23103482
[TBL] [Abstract][Full Text] [Related]
19. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
20. Degludec: a novel basal insulin.
Kalra S; Baruah MP; Niazi AK
Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
